Helius Medical Technologies (HSDT)
(Delayed Data from NSDQ)
$0.76 USD
-0.04 (-4.51%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $0.76 0.00 (-0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HSDT 0.76 -0.04(-4.51%)
Will HSDT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HSDT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HSDT
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
HSDT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
How Much Upside is Left in Helius Medical Technologies, Inc. (HSDT)? Wall Street Analysts Think 1183.3%
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
Other News for HSDT
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Helius Medical Technologies Inc (HSDT) Q2 2024 Earnings Call Transcript Highlights: Revenue ...
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript
HSDT Stock Earnings: Helius Medical Tech Misses EPS, Beats Revenue for Q2 2024